Available online 7 February 2017 Bone is in a constant state of remodeling, a process which was once attributed solely to osteoblasts and osteoclasts. Decades of research has identified many other populations of cells in the bone that participate and mediate skeletal homeostasis. Recently, osteal macrophages emerged as vital participants in skeletal remodeling and osseous repair. The exact mechanistic roles of these tissue-resident macrophages are currently under investigation. Macrophages are highly plastic in response to their micro-environment and are typically classified as being proor anti-inflammatory (pro-resolving) in nature. Given that inflammatory states result in decreased bone mass, proinflammatory macrophages may be negative regulators of bone turnover. Pro-resolving macrophages have been shown to release anabolic factors and may present a target for therapeutic intervention in inflammationinduced bone loss and fracture healing. The process of apoptotic cell clearance, termed efferocytosis, is mediated by pro-resolving macrophages and may contribute to steady-state bone turnover as well as fracture healing and anabolic effects of osteoporosis therapies. Parathyroid hormone is an anabolic agent in bone that is more effective in the presence of mature phagocytic macrophages, further supporting the hypothesis that efferocytic macrophages are positive contributors to bone turnover. Therapies which alter macrophage plasticity in tissues other than bone should be explored for their potential to treat bone loss either alone or in conjunction with current bone therapeutics. A better understanding of the exact mechanisms by which macrophages mediate bone homeostasis will lead to an expansion of pharmacologic targets for the treatment of osteoporosis and inflammation-induced bone loss.
Introduction
The skeleton is a complex organ that provides structural support, protection of the body's internal organs, houses the hematopoietic system, and serves as a reservoir of calcium. Bone is in a constant state of turnover which is balanced by bone formation and resorption; processes which are controlled by the activity of bone resident cells: osteoblasts, osteocytes, and osteoclasts. The bone and bone marrow consist of several other cells that play crucial supportive roles in the process of homeostatic bone turnover including, but not limited to, T and B cells, mast cells, and monocytes/macrophages (Chang et al., 2008; Frame & Nixon, 1968; Li, Toraldo, et al., 2007; Sinder, Pettit, & McCauley, 2015; Xiao, Wang, Pacios, Li, & Graves, 2016 ). An imbalance in the bone remodeling process due to alterations in osteoblast or osteoclast activity can lead to elevated bone mass (increased osteoblast activity or decreased osteoclast activity) or decreased bone mass (decreased osteoblast activity or increased osteoclast activity).
Approximately 44 million Americans have low bone mass, placing them at a high risk of developing osteoporosis, a disease affecting over 10 million Americans (Office, 2004) . Loss of bone mass leads to increased fracture risk, which has a high rate of morbidity and mortality in the elderly population (Cooper, Atkinson, Jacobsen, O'Fallon, & Melton, 1993) . Osteoporosis-related fractures often lead to hospitalizations and nursing home placement, decreasing the patient's quality of life and posing a large burden on healthcare systems. Bone loss leading to osteoporosis has been widely studied in the context of menopause and estrogen deficiency and is associated with an increase in osteoclast activity relative to osteoblast activity (Odell & Heath, 1993) . Estrogen does not likely mediate osteoclast activity directly, however the withdrawal of estrogen results in the increased production of inflammatory cytokines (Pacifici et al., 1991) . These inflammatory mediators are major contributors in the increased osteoclast activity seen in menopause-associated bone loss. An early study by Horton et al. demonstrated that osteoclasts which were exposed to activated leukocyte cell supernatant increased osteoclast number and activity (Horton, Raisz, Simmons, Oppenheim, & Mergenhagen, 1972) . This finding led to a large body of research investigating various proinflammatory factors and their role in osteoclast stimulation. Some of these proinflammatory cytokines which have been shown to increase osteoclastic differentiation and activity include tumor necrosis factor alpha (TNF-α) (Bertolini, Nedwin, Bringman, Smith, & Mundy, 1986; Kimble et al., 1995; Konig, Muhlbauer, & Fleisch, 1988; Thomson, Mundy, & Chambers, 1987; van der Pluijm et al., 1991) , prostaglandins (Raisz, 1999) , interleukin-1 (IL-1) (Boyce, Aufdemorte, Garrett, Yates, & Mundy, 1989; Dewhirst, Stashenko, Mole, & Tsurumachi, 1985; Gowen, Wood, Ihrie, McGuire, & Russell, 1983; Kimble et al., 1995; Konig et al., 1988; Lorenzo et al., 1998) , IL-6 (Ishimi et al., 1990; Jilka et al., 1992; Poli et al., 1994) , IL-11 (Girasole, Passeri, Jilka, & Manolagas, 1994; Hill, Tumber, Papaioannou, & Meikle, 1998) , IL-15 (Ogata et al., 1999) , and IL-17 (Kotake et al., 1999) . The increase in osteoclast differentiation is in large part due to an increase in receptor activator of nuclear factor kappa-B ligand (RANKL) production in target cells. RANKL binds to RANK on pre-osteoclasts and induces differentiation. However, it has been shown that TNF-α can induce osteoclast differentiation when RANKL levels are lower than necessary for osteoclastogenesis (Kobayashi et al., 2000) .
Increased proinflammatory cytokine production is not only seen in during estrogen withdrawal but is also associated with various inflammatory diseases. Systemic and/or local bone loss is often seen in patients with inflammatory diseases (Mundy, 2007; Romas & Gillespie, 2006) including systemic lupus erythematous (Garcia-Carrasco et al., 2009) , rheumatoid arthritis (Gough, Lilley, Eyre, Holder, & Emery, 1994; Gravallese et al., 1998; Roldan, Del Rincon, & Escalante, 2006) , cystic fibrosis (Shead, Haworth, Barker, Bilton, & Compston, 2010) , chronic obstructive pulmonary disease (Dam et al., 2010) , inflammatory bowel disease (IBD) (Ali, Lam, Bronze, & Humphrey, 2009; Paganelli et al., 2007) , and periodontal disease (Yoshihara, Seida, Hanada, & Miyazaki, 2004) . The inflammatory process is a complex response which is mediated by various cells of the innate and adaptive immune systems. The direct effect of inflammatory cytokines on osteoclast activity has been well studied, and the cells mediating these effects are becoming more appreciated for their roles in bone homeostasis.
The focus of this review is the role of immune cells, specifically monocyte/macrophages, on the maintenance of bone and their contributions to bone disease. Additionally, the therapeutic potential of targeting osteal macrophages in bone-related diseases will be highlighted.
2. Translating traditional macrophage actions to their roles in bone 2.1. Macrophages in non-bone tissue Macrophages, Greek for "big eaters," were first described by Elie Metchnikoff over 100 years ago and are traditionally known for their phagocytic roles in inflammation and immunity (Gordon, 2008) . They are a heterogeneous population of cells with multiple phenotypes whose function is based on surrounding environmental cues. These macrophage phenotypes, commonly referred to as polarizations, were once considered to be distinct populations which could be divided into M1 (classically activated) or M2 (alternatively activated) subsets (Gordon & Martinez, 2010; Gordon & Taylor, 2005) . A large body of research has focused on defining these populations of cells, and it has become clear that macrophage polarization cannot simply be divided into two unique populations, but rather consists of a spectrum of phenotypes (Mabbott, Kenneth Baillie, Hume, & Freeman, 2010; Mosser & Edwards, 2008; Ravasi et al., 2002) . A collaboration between multiple groups has worked together to create a set of standards which outline the sources of macrophages, activators of macrophages, and defines various markers of macrophage activation (Murray et al., 2014) . Due to the heterogeneity of macrophages, the original definitions of these cells are no longer categorized as M1 or M2. Not only have subcategories been identified such as M2a, M2b, and M2c (Biswas & Mantovani, 2010) , but the original two designations are currently referred to as "M1-like" and "M2-like," due to the overlap of the expression of markers.
M1-like or classically-activated macrophages are defined for their role in mediating an inflammatory response. They polarize toward the M1 phenotype in response to inflammatory cytokines released from Th1 cells, such as IL-1 and IL-6. M2-like macrophages are present during the resolution phase of inflammation and are responsible for antiinflammatory cytokine production and enhanced clearance of apoptotic cells, termed efferocytosis (Bystrom et al., 2008; deCathelineau & Henson, 2003; Xu et al., 2006) . Exposure to anti-inflammatory cytokines IL-4, IL-12 and IL-10 leads to M2-like macrophage polarization (Mantovani et al., 2004) , and increased apoptotic cell clearance (Lingnau, Hoflich, Volk, Sabat, & Docke, 2007; Michalski, Koh, Weidner, Roca, & McCauley, 2016; Ogden et al., 2005) .
Tissue-resident macrophages are found in nearly all tissues other than hyaline cartilage, and play additional roles other than immunity and inflammation, including supporting tissue homeostasis, clearance of debris and tissue repair (Davies, Jenkins, Allen, & Taylor, 2013; Davies & Taylor, 2015; Gordon, Pluddemann, & Martinez Estrada, 2014; Wynn & Vannella, 2016) . The differentiation and maintenance of tissue-resident macrophages is unique compared to that of adult hematopoietic cell renewal via hematopoietic stem cells (HSCs). It has recently been shown that many adult tissue-resident macrophages differentiate from a Tie2 + cellular pathway which leads to yolk sacderived myeloid progenitors that develop prior to the appearance of HSCs (Gomez Perdiguero et al., 2015; Mass et al., 2016) . This distinction is important because the unique origin and differentiation of tissue macrophages has significant relevance to disease.
Tissue-resident macrophages perform specific functions based on the tissue in which they reside. For example, the lung consists of alveolar macrophages which survey for inhaled pathogens and regulate homeostasis of the tissue through surfactant clearance (Carey & Trapnell, 2010; Gautier et al., 2012; Maus et al., 2002) . Kupffer cells in the liver participate in the clearance of aged erythrocytes (Klein et al., 2007) . Fig. 1A depicts several of the tissue-resident macrophages. Of interest to this review, the bone and bone marrow microenvironment maintains several tissue-resident macrophage populations, each with distinct locations and functions.
Macrophages in bone homeostasis

Osteal macrophages
The bone and bone marrow consist of three known distinct macrophage populations: bone marrow macrophages (erythroid island macrophages and hematopoietic stem cell macrophages), osteoclasts, and a recently defined population of macrophages termed osteal macrophages or "osteomacs" (Chang et al., 2008) (Fig. 1B) . Historically, bone marrow macrophages have been studied in the context of erythropoiesis (Chow et al., 2013; Sadahira & Mori, 1999) and hematopoietic stem cell niche maintenance (Chow et al., 2011; Kaur et al., 2016) . Osteoclasts have long been identified as the tissue-resident macrophages in bone, although they now share this designation with the other bone macrophage populations. Osteoclasts differentiate down the monocyte lineage, and fuse to become multinucleated tartrate-resistant acid phosphatase (TRAP)-positive cells. Osteal macrophages are a distinct subset of bone macrophages located in close proximity to the bone surface and are F4/80-positive (Fig. 2) (Hume, Loutit, & Gordon, 1984) and TRAP-negative (Chang et al., 2008) . These osteal macrophages were characterized and found frequently located next to active bone forming osteoblasts. The majority of osteoblasts on the inner surface of cortical bone are covered in F4/80 +, CD68 +, Mac-3+, TRAP− macrophages (Wu, Raggatt, Alexander, & Pettit, 2013) . Table 1 details the known markers and functions of the four macrophages present in bone. The specific myeloid progenitors and functional roles of the osteal macrophage are currently under investigation. The proximity to the bone forming unit suggests that they communicate with bone resident cells and play a supportive role in the bone remodeling process.
Role of osteal macrophages: macrophage ablation experiments
To investigate the functional role of osteal macrophages, several in vitro assays have identified a supportive role for macrophages in mediating bone formation. An early study by Champagne, Takebe, Offenbacher, and Cooper (2002) demonstrated that human and murine macrophages produce bone morphogenetic proteins (BMPs), specifically BMP-2 and BMP-6. Mesenchymal stem cells (MSCs) (osteoblast progenitor cells) grown in conditioned media from J774A.1 macrophage Erythroid island macrophages (EIM) are found interacting with and supporting erythroblasts during erythropoiesis. These macrophages are distinct from HSC niche macrophages which are found adjacent to blood vessels and support HSC self-renewal and cycling. Osteal macrophages are found adjacent to bone forming cells (osteoblasts), dormant bone-lining cells, and osteoclasts. The functional role of osteal macrophages is proposed to support bone formation through mechanisms currently under investigation. Fig. 2 . F4/80 positive cells are located throughout the marrow and intimately associated with bone surfaces. Tibiae from 22-week old C57BL/6 mice were paraffin embedded, sectioned and immunohistochemical stained (brown) for F4/80 and counterstained with hematoxylin (blue) as previously described (Cho et al., 2014) . Macrophages are located adjacent to bone surfaces (black arrowheads) and throughout the marrow space. F4/ 80+ cells are also associated with blood vessels (BV) and support hematopoiesis (red arrowheads). cells displayed increased osteoblast differentiation gene expression, and treatment of macrophages with anti-BMP-2 prevented the proosteogenic effect (Champagne et al., 2002) . Primary cell cultures which are used to assess osteoblastogenesis and mineralization consist of a heterogeneous population of cells. To measure the contribution of macrophages in these cultures, primary calvarial osteoblast cultures were sorted for macrophage markers and found to consist of 11% to 17% F4/80 + macrophages (Chang et al., 2008) . When macrophages were depleted from cultures using a magnetic sorting technique, mineralization and osteoblastic differentiation gene expression was significantly reduced (Chang et al., 2008) . Nicolaidou et al. (2012) also found that monocytes/macrophages induce human MSC differentiation into osteoblasts and increase mineralization. Increased oncostatin M (OSM) production by monocytes led to upregulation of signal transducer and activator of transcription 3 (STAT3) in MSCs and enhanced differentiation. Neutralizing antibody to OSM decreased MSC differentiation into osteoblasts (Nicolaidou et al., 2012) . These findings were supported by a study showing that OSM produced by activated circulating CD14+ or bone marrow CD11b + monocytes/macrophages induced osteoblast differentiation and matrix mineralization from human mesenchymal stem cells (Guihard et al., 2012) . Treatment of MSCs with recombinant OSM also stimulated osteoblast differentiation (Fernandes et al., 2013) .
These in vitro data support the hypothesis that macrophages are important in mediating osteoblastic differentiation and mineralization. In vivo macrophage ablation models further support these findings. The macrophage Fas-induced apoptosis (MAFIA) mouse model results in depletion of colony-stimulating factor-1 receptor (c-Fms) positive myeloid lineage cells upon administration of AP20187 (Burnett et al., 2006 (Burnett et al., , 2004 . MAFIA mice administered AP20187 displayed markedly reduced osteoblast lining bone surfaces, decreased bone formation, and an overall reduction in bone volume (Chang et al., 2008; Cho et al., 2014; Winkler et al., 2010) . Another method to deplete macrophages is the lysozyme-M (LysM) driven cre model. LysM is expressed in cells of the myeloid lineage (Clausen, Burkhardt, Reith, Renkawitz, & Forster, 1999) and when LysMcre mice were crossed with R26RDTA mice, LysM expressing cells including monocytes and macrophages were depleted . Macrophage depletion using the LysMcre-DTA model led to decreased bone growth in young mice and osteoporosis in skeletally mature mice .
Given that osteoclasts and macrophages differentiate from the monocytic lineage, macrophage ablation experiments targeting either c-Fms or LysM should also affect osteoclasts. In the MAFIA mouse model using c-fms driven macrophage depletion, Cho et al. (2014) demonstrated that the dosing regimen of AP20187 used successfully depleted macrophage populations without altering the number of osteoclasts per bone surface in vivo. Conversely, Vi et al. (2015) demonstrated in the LysM model of macrophage depletion that osteoclasts were present in macrophage depleted mice, however they were reduced and less active. In vitro assays of osteoclast resorptive potential showed that osteoclasts from the LysM mice were still functional at resorbing bone. It is important, therefore, that models of macrophages depletion used to investigate bone phenotypes, should consider the potential osteoclast effects. Taken together, these studies show that macrophages are important and necessary contributors to the bone modeling and remodeling process. Their mechanistic roles are under ongoing investigation.
Efferocytosis: a role for osteal macrophages?
Macrophages are well known for their role as professional phagocytes. As mentioned previously, macrophages can be polarized based on the environment in which they reside. M1-like macrophages participate in the inflammatory response and are primed by proinflammatory cytokines. Proinflammatory cytokines enhance osteoclast differentiation and resorption by upregulation of RANKL, resulting in low bone mass phenotypes. M2-like macrophages, on the other hand, are considered resolution phase macrophages and participate in the clearance of apoptotic cells, termed efferocytosis, following an inflammatory milieu (deCathelineau & Henson, 2003; Hochreiter-Hufford & Ravichandran, 2013; Poon, Lucas, Rossi, & Ravichandran, 2014; Ravichandran, 2010) . Under normal conditions, approximately one million cells in the body become apoptotic each second, and the effective clearance of these apoptotic cells is crucial to prevent an abnormal inflammatory response or systemic autoimmunity (Baumann et al., 2002; Munoz, Lauber, Schiller, Manfredi, & Herrmann, 2010; Shao & Cohen, 2011) . The bone marrow is a complex organ that consists of millions of cells which undergo turnover daily, resulting in a large amount of apoptotic cells to be cleared. To maintain homeostasis, these cells must be rapidly and effectively cleared. In regards to the bone forming unit cells, osteoblasts have three fates: they become bone-lining cells, osteocytes or undergo apoptosis. Of the osteoblasts initially at remodeling sites, more than 50% are thought to undergo apoptosis (Jilka, Weinstein, Bellido, Parfitt, & Manolagas, 1998) . The role of pro-resolving macrophages and the process of efferocytosis have recently surfaced in bone, and studies investigating apoptotic cell clearance may lead to a better understanding of the functional role of osteal macrophages. Macrophage polarization is of interest in the context of bone and may provide clues into the functional role macrophages play in skeletal homeostasis (Horwood, 2016) . Macrophage expression of the osteoinductive factors BMP-2 and BMP-6 was reduced when macrophages were stimulated with lipopolysaccharide (LPS), a known proinflammatory M1 macrophage mediator (Champagne et al., 2002) . Conditioned media from macrophages treated with LPS were unable to produce the stimulatory effect on MSC differentiation into osteoblasts (Champagne et al., 2002) . This suggests that proinflammatory mediators may result in reduced bone phenotypes by altering macrophage expression of osteoinductive factors. Furthermore, conditioned media from macrophages treated with IL-4 and M-CSF (M2 activation) increased osteoblast maturation from MSCs, whereas macrophages treated with granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-gamma and LPS (M1 activation) did not (Fernandes et al., 2013) . These findings support alternatively activated macrophages as mediators of bone homeostasis.
The functional role of macrophages and the participation of efferocytosis in bone remodeling is further supported by macrophage ablation experiments. The depletion of myeloid lineage cells via the MAFIA mouse model resulted in decreased F4/80+ cells, CD68+ cells, and reduced bone mass (Cho et al., 2014) . In the same study, clodronate-loaded liposomes were administered to mice to deplete mature macrophages with phagocytic capacity. This method of macrophage ablation also led to a decrease in F4/80 + cells, however, CD68 + and CD163 + cells were reciprocally increased as was bone mass. CD68+ and CD163+ cells are mature phagocytic macrophages that participate in the process of efferocytosis. It is hypothesized that these cells were increased after administration of the clodronate liposomes in a positive feedback mechanism (Cho et al., 2014) . To further support the hypothesis that the increase in CD68 + cells in the clodronate model also coincided with increased apoptotic cell clearance, TUNEL staining verified a reduction in apoptotic cells in the clodronatetreated mice compared to the MAFIA mouse model. Furthermore, clodronate-treated mice displayed increased whole bone marrow gene expression of M2-related genes and no change in M1-related genes (Cho et al., 2014) . Furthermore, the clodronate-liposome treatment resulted in increased expression of osteogenic genes including Wnt-10b and TGF-β1. The increased bone mass in the clodronate model of macrophage depletion suggests a correlation between the process of apoptotic cell clearance and bone turnover.
During programmed cell death, cells begin to expose phosphatidylserine (PS) on their outer membrane. Phagocytic cell receptors recognize PS on apoptotic cells which leads to signaling and initiates engulfment of the apoptotic cell (Ravichandran, 2010; Ravichandran & Lorenz, 2007) . Milk fat globule-epidermal growth factor 8 (MFG-E8), also known as lactadherin, is a secreted protein which forms a bridge between PS on the apoptotic cell and the vitronectin receptor (α v β 3 integrin) on the phagocyte. MFG-E8 knockout mice displayed decreased bone mass and accelerated bone loss due to ovariectomy (Sinningen et al., 2015) . Cell autonomous studies revealed MFG-E8 knockout osteoblasts mice had decreased mineralization and knockout osteoclasts were more active. The phagocytic capacity of bone marrow macrophages were not assessed in this study but were shown to have decreased phagocytosis by others . These data suggest that MFG-E8 may have direct roles in osteoblast and osteoclast activity, but MFG-E8-mediated efferocytosis by macrophages may also contribute to the low bone mass phenotype seen in these mice. Further investigation into the direct effects of efferocytosis on bone turnover is important in better delineating the mechanistic roles of macrophages in mediating bone homeostasis.
Recent studies have begun to define the role macrophage-mediated clearance of apoptotic bone cells on bone turnover (McCauley, Dalli, Koh, Chiang, & Serhan, 2014; Michalski et al., 2016) . Live cell imaging shows that bone marrow derived macrophages readily engulf apoptotic MC3T3 (osteoblastic) cells, resulting in complete clearance . Similarly, bone marrow macrophages engulf apoptotic primary bone marrow stromal cells as shown using flow cytometric analysis in conjunction with ImageStream analysis (Fig. 3) . IL-10 was investigated as a mediator of apoptotic bone marrow stromal cell clearance (Michalski et al., 2016) . Bone marrow derived macrophages primed with IL-10 displayed enhanced efferocytosis of apoptotic bone cells and mimicked an M2-like phenotype (CD206 +). Following engulfment of apoptotic bone marrow stromal cells or MC3T3 cells, macrophages secreted the osteogenic molecule TGF-β1 and monocyte cell attractant chemokine (C-C motif) ligand 2 (Michalski et al., 2016) . These factors were upregulated in comparison to the engulfment of apoptotic neutrophils, suggesting that efferocytosis of apoptotic bone cells leads to a distinct expression profile which may aid in the recruitment of progenitor cells to repopulate the dead/dying cell populations. The exact mechanistic role of osteal macrophages in supporting bone turnover is currently being investigated, and efferocytosis shows potential to positively regulate these processes.
Macrophages in bone disease
Tissue homeostasis requires a tightly organized system of various cell types working together to maintain balance. If the balance is disrupted, the progression of aberrant disease states may persist. While a direct link between macrophage function and bone-related diseases has not been thoroughly investigated, there are clear macrophage phenotypes which present in various disease states. As mentioned previously, proinflammatory mediators enhance osteoclastogenesis and activity in part due to upregulation of RANKL. Increased inflammatory cytokines have been associated with post-menopausal osteoporosis, yet the in vivo characterization of bone marrow or osteal macrophage phenotypes under these conditions is not known. It may be speculated that increased inflammatory cytokines encourages a shift in macrophage phenotypes toward M1-like. The exact role of macrophages in osteoporosis is as yet unknown.
During aging, repair processes, including fracture repair, often become less efficient (Gruber et al., 2006; Lopas et al., 2014) . The cellular processes which are impaired in aging are under investigation. When bone marrow from 4 week old mice was transplanted into 12 month old mice, fracture healing was enhanced in the older mice (Xing, Lu, Hu, Miclau, & Marcucio, 2010) . The positive effects were attributed to the young inflammatory cells aiding in the repair processes. Additionally, parabiosis experiments showed that youthful circulating factors mediated repair processes in aged mice . While the bone marrow transplants and parabiosis studies result in the exchange of a heterogeneous population of cells, macrophages may play a contributory role. In fact, in other tissues, macrophages have been shown to be less effective at tissue repair with age (Scheib & Hoke, 2016) . Aging also coincides with an increase in proinflammatory mediators, decrease in M2-like macrophages, and decrease in phagocytic capacity (Ferrandez & De la Fuente, 1999; Franceschi et al., 2000 Franceschi et al., , 2007 Izgut-Uysal, Ozkaya, Ozdemir, Yargicoglu, & Agar, 2004; Li, 2013; Plowden, Renshaw-Hoelscher, Engleman, Katz, & Sambhara, 2004) .
Rheumatoid arthritis displays local and systemic bone loss and is associated with joint destruction. The exact pathogenesis of rheumatoid arthritis is unknown, yet macrophage activation contributes greatly to its presentation. Macrophages have been shown to be an important source of proinflammatory cytokines such as IL-1β, IL-6, TNF-α and GM-CSF locally and systemically (Kinne, Brauer, Stuhlmuller, Palombo-Kinne, & Burmester, 2000; Liote, Boval-Boizard, Weill, Kuntz, & Wautier, 1996) . The increased proinflammatory cytokines enhance osteoclast differentiation and activity via upregulation of RANKL, and leads to bone destruction. Macrophages and their byproducts have become candidate targets in the treatment of rheumatoid arthritis, and include anti-TNF antibodies and the inhibition of c-Fms (Davignon et al., 2013) . However, it is proposed that specifically targeting proinflammatory M1-like macrophages may result in more positive results than depletion of all macrophages (Li, Hsu, & Mountz, 2012) . Additionally, mice deficient in MFG-E8, a protein that mediates apoptotic cell clearance, have exacerbated rheumatoid arthritis presentation (Albus et al., 2016) . While macrophages were not characterized in this study, the known role of MFG-E8 in M2-mediated clearance of apoptotic cells suggests that M2 macrophages may be important in preventing rheumatoid arthritis symptoms by aiding in inflammation resolution and debris clearance.
Osteonecrosis of the jaw (ONJ) presents as exposed necrotic bone in the oral cavity. ONJ is often associated with high-dose intravenous antiresorptive therapies used in patients with metastatic bone disease (Khan et al., 2015) . The exact etiology is not known for ONJ, but inflammatory macrophages have recently been shown to play a role (Zhang et al., 2013) . Increased IL-17 correlated with an increase in M1 to M2 macrophage ratio in patients ONJ lesions. Adoptive transfer of M2 macrophages expanded ex vivo decreased ONJ severity, IL-17 production and M1 to M2 ratio in a mouse model for ONJ (Zhang et al., 2013) . Neutralizing antibody to IL-17 also decreased the M1 to M2 ratio and disease prevalence in mice. These data suggest that M1 macrophages correlate with ONJ disease presentation and severity, and targeting M1 macrophage activation by IL-17 may serve as a potential therapeutic for patient at risk for developing ONJ lesions.
Macrophages in bone repair
Macrophages function to maintain normal tissue homeostasis and play a crucial role in tissue damage repair. This is also true in osseous wound healing. Following a fracture, bone is regenerated to fill in the fracture space to restore form and function. After tissue injury, damaged tissue and apoptotic cells are abundant and must be cleared to allow for proper modeling of the site. Bone healing generally involves five stages: the inflammatory response, soft callus formation, hard callus formation, union, and bone remodeling (reviewed in (Schindeler, McDonald, Bokko, & Little, 2008) . The initial inflammatory response provides an influx of cells, including macrophages. Macrophages are important in the early stages of bone healing, yet their more crucial role has been shown to be during the subsequent anabolic steps in bone repair. The MAFIA mouse model was used to assess the macrophage contribution to healing via intramembranous ossification or endochondral ossification (Alexander et al., 2011; Raggatt et al., 2014) . In both models of repair, macrophage depletion at the time of injury resulted in substantially reduced collagen type-I deposition and bone mineralization leading to impaired bone repair. Vi et al. (2015) utilized the macrophage depletion LysMcre-DTA model and similarly found that macrophage depletion significantly impaired tibial fracture healing. To better assess the role of macrophages in the later stages of fracture healing, the MAFIA mouse model was also utilized to deplete macrophages after the initial inflammatory events and prior to the anabolic phase. Interestingly, macrophage depletion during this phase also led to decreased healing (Alexander et al., 2011; Raggatt et al., 2014) . These data suggest that macrophages are important during various stages of bone repair and are necessary for proper healing. Additionally, this may implicate different macrophage phenotypes during healing as the initial inflammatory macrophages may be distinct from those present during the anabolic phase. Indeed, inflammatory and osteal macrophages predominate in different locations within fracture sites, further supporting separate functional roles (Alexander et al., 2011; Raggatt et al., 2014) . Clearly, macrophages present a possible therapeutic target for enhancing fracture healing.
The mechanisms by which macrophages exert their positive effects on bone formation are not clearly understood. Guihard et al. (2015) expanded on their in vitro findings that OSM produced by macrophages supports osteoblastic mineralization by investigating signaling during tibial injury healing. They found that OSM expression was increased during the inflammatory phase of healing and that macrophage depletion via the clodronate-loaded liposome model led to decreased OSM expression (Guihard et al., 2015) . Furthermore, OSM and OSM receptor null mice had fewer osteoblasts and less bone formation within the injury site. These data support OSM as an important pro-anabolic molecule in the healing of bone and a potential target for fracture healing therapeutics. Macrophages can secrete other osteoinductive factors (TGF-β1, BMP-2, BMP-4, BMP-6), which have only begun to be explored in the context of macrophage-mediated osseous wound healing. Macrophages are implicated in the heterotopic ossification that occurs following tissue injury due to trauma and burns playing an important role as immune effector cells in ectopic bone formation (Kraft et al., 2016) . One study demonstrated a role for macrophage derived BMP4 in a genetic mouse model where soft tissue injuries led to bone with marrow in extraskeletal tissues (Kan et al., 2009) . As macrophages are typically at the interface of the adaptive and innate immune systems and have both inflammatory and antiinflammatory phenotypes, their ability to orchestrate osseous wound healing in various scenario requires further study. 
Current osteoporosis therapies and how they affect macrophages
Antiresorptives
Antiresorptives are commonly used therapeutics to combat the bone loss associated with osteoporosis secondary to menopause or systemic inflammation as well as to treat metastatic bone diseases and hypercalcemia. Broadly, antiresorptives inhibit osteoclast activity, either through targeting key differentiation steps or preventing mechanisms which osteoclasts use to adhere to and resorb bone. The most common category of antiresorptives used clinically are the bisphosphonates.
Bisphosphonates attach to hydroxyapatite in bone and are incorporated into osseous surfaces. Depending on the structure of the bisphosphonate, as osteoclasts resorb bone that has incorporated bisphosphonates, the bisphosphonates inhibit osteoclast activity or induce apoptosis. Nitrogen-containing bisphosphonates inhibit farnesyl pyrophosphate synthase leading to impaired ability to adhere to bone and produce protons necessary for resorption (Rodan & Fleisch, 1996; Sato et al., 1991) . Simple bisphosphonates on the other hand do not contain nitrogen. These molecules are metabolized by osteoclasts to a toxic analogue of adenosine triphosphate (ATP) resulting in osteoclast apoptosis (Hughes et al., 1995; Rogers, 2004) . The effects of bisphosphonates on osteoclasts have been widely studied, yet the effects on macrophages are just becoming apparent (Roelofs, Thompson, et al., 2010) . The phagocytic nature of macrophages makes them susceptible to uptake of bisphosphonates (Coxon, Thompson, Roelofs, Ebetino, & Rogers, 2008; Roelofs, Coxon, et al., 2010) . Macrophages treated in culture with nitrogen-containing bisphosphonates versus simple bisphosphonates responded differently. Simple bisphosphonates reduced inflammatory cytokine (IL-1β, IL-6, nitric oxide) production by macrophages whereas nitrogen-containing bisphosphonates enhanced IL-1β and IL-6 production (Makkonen et al., 1999; Pennanen, Lapinjoki, Urtti, & Monkkonen, 1995) . These results indicate that bisphosphonates alter cytokine release profiles by macrophages and may therefore alter their interactions with bone cells. Bisphosphonates have also been shown to decrease osteoclastogenesis (Hughes, MacDonald, Russell, & Gowen, 1989; Lowik, van der Pluijm, van der Wee-Pals, van Treslong-De Groot, & Bijvoet, 1988) . Osteoclast precursors are of the monocyte-macrophage lineage and may also be altered in the process of reduced osteoclastogenesis. The exact alterations in these cell populations are not appreciated, but further understanding may allow for better tailored osteoporosis therapies.
Denosumab is also an antiresorptive, yet its mechanism of action is different than bisphosphonates. Denosumab is a human monoclonal antibody that binds to RANKL which selectively inhibits osteoclastogenesis. It is FDA approved for the treatment of postmenopausal osteoporosis for women with high or increased fracture risk (Cummings et al., 2009 ). Due to its long half-life, administration of denosumab for the treatment of osteoporosis is once every six months, making it more manageable than daily or weekly bisphosphonates (Bekker et al., 2004) . Monocytes and macrophages express RANK, the receptor for RANKL. Interestingly, studies have shown that denosumab does not alter the functions of monocytes (Ferrari-Lacraz & Ferrari, 2011; Seshasayee et al., 2004) . Additionally, denosumab was not shown to alter differentiation or viability of macrophages from monocytes (Hoefert et al., 2015) . Reports of severe infections as low incidence adverse events in cancer patients taking denosumab have not surfaced in osteoporosis patients, yet raise the potential for high doses impacting aspects of the host response (Burkiewicz, Scarpace, & Bruce, 2009 ). While studies do not imply that denosumab changes macrophage differentiation, further exploration of macrophage responses to RANKL inhibitors seems prudent.
Odanacatib is a cathepsin K inhibitor, a key enzyme utilized by osteoclasts to break down bone. Recently, Merck discontinued its clinical trials of odanacatib due to stroke risk, however cathepsin K inhibition should not be ruled out as a target for treating reduced bone mass.
Odanacatib has been shown to suppress inflammation and macrophage numbers in sites with increased inflammation such as periodontal and endodontic lesions (Hao, Chen, McConnell, et al., 2015; Hao, Chen, Zhu, et al., 2015) . This result is an important finding for the potential treatment of inflammation-induced bone loss. The mechanism by which odanacatib alters macrophages is not clear. Given that macrophages are important cells for the maintenance and turnover of bone, there is a need for further identification of the effects on macrophages by bone therapeutics. Off target effects of drugs may be due to macrophage responses versus traditional bone cell effects.
Anabolic agents
Antiresorptives are the most widely used therapeutic for the treatment of osteoporosis where they prevent further loss of bone in patients already exhibiting low bone mass. Due to the impact on reducing ongoing resorption, these agents provide increases in bone yet they do not stimulate bone formation. Teriparatide (hPTH 1-34) is the only anabolic osteoporosis therapeutic that has current US FDA approval. PTH-like analogs (ex. Abaloparatide) are currently under clinical investigation (Miller et al., 2016) . Parathyroid hormone (PTH), when pathologically elevated in the body or administered continuously, is catabolic in nature and acts as a signal to sequester calcium from the skeleton. However, if PTH is administered intermittently, an anabolic response leads to a net increase in bone (Ejersted, Andreassen, Hauge, Melsen, & Oxlund, 1995; Finkelstein et al., 2003) . Teriparatide is currently only reserved for severe cases of osteoporosis due to its high cost, delivery method (injection), and black box warning attributed to the development of osteosarcomas in rats treated intermittently with PTH (Okazaki, 2003) . (Okazaki, 2003) . Any increase in risk of osteosarcoma in humans has not surfaced in the fourteen years it has been in clinical use (Cipriani, Irani, & Bilezikian, 2012; Elraiyah, Gionfriddo, & Murad, 2015) . The exact mechanism of the anabolic response is still being investigated, and a better understanding of the effects of teriparatide will allow it to reach more patients with osteoporosis, to aid in the healing of fractures, and serve to treat patients with inflammatory diseases resulting in bone loss. Additionally, the delivery method is currently via subcutaneous injection and is administered systemically. Local delivery of teriparatide is under investigation for local bone regenerative application (Dang, Koh, Danciu, McCauley, & Ma, 2016; Dang, Koh, Jin, McCauley, & Ma, 2017; Liu, Pettway, McCauley, & Ma, 2007) . In rats, local intra-oral administration of PTH was as effective as subcutaneous injection in enhancing hard and soft tissue healing following tooth extraction (Kuroshima, Kovacic, Kozloff, McCauley, & Yamashita, 2013) . Such application could have a positive impact in conditions such as periodontal disease, bone defects or fractures where systemic administration has a demonstrated benefit (Bashutski et al., 2010; Ellegaard, Jorgensen, & Schwarz, 2010 ) but systemic application is unnecessary.
The role of macrophages has been outlined in the context of homeostatic bone turnover, disease and healing. Their role in mediating aspects of the PTH anabolic response is currently under investigation. Intermittent PTH treatment has been shown to be more effective when immune cells, such as macrophages, are present (Cho et al., 2014) . In a clinical trial investigating the effect of local teriparatide treatment of periodontal defects, disease sites displayed an anabolic response to teriparatide therapy, whereas non-diseased, non-inflamed sites showed no change in the same patient (although the study was not designed specifically to address this endpoint) (Bashutski et al., 2010) . Additionally, the anabolic response is more robust in sites of injury such as tibial fracture, tooth extraction sockets, and endodontic lesions versus non-wounded bone (Kuroshima, Entezami, McCauley, & Yamashita, 2014; Otawa, Tanoue, Kido, Sawa, & Yamashita, 2015) . These findings led to the hypothesis that cells mediating the inflammatory process may be supportive of the anabolic response of intermittent PTH treatment.
The role of macrophages in mediating the anabolic response to intermittent PTH comes from mouse models of macrophage ablation. Mice treated with intermittent PTH display increased bone mass and an increase in F4/80-positive cells lining the periosteal and endosteal bone surfaces (Cho et al., 2014) . In the same study, macrophages were ablated using the MAFIA mouse model and mice were treated with intermittent PTH. The anabolic response was lost in the mice with depleted macrophages. Interestingly, when macrophages were depleted using clodronate-loaded liposomes, the anabolic response was amplified. This led to an investigation of the subsets of macrophages which were altered in the two macrophage ablation models. CD68-positive macrophages are mature macrophages which demonstrate phagocytic capacity. In the MAFIA mouse model, all macrophages were depleted including CD68-positive macrophages. Conversely, in the clodronateloaded liposome model, CD68-positive macrophages were amplified, an increase which may reflect a compensatory feedback loop (Cho et al., 2014 ). These observations not only implicate a role for macrophages in the anabolic response to intermittent PTH therapy, but also demonstrate that particular macrophage subsets are necessary for the PTH response. Further investigation of the clodronate model showed an increase in whole bone marrow osteogenic gene expression including Wnt-3a, Wnt-10b and TGF-β1, all of which were further increased with PTH treatment (Cho et al., 2014) . The source of the increase in gene expression is likely from a heterogeneous population of cells, but may be attributed to downstream effects of the increased CD-68 + cells and M2 macrophage upregulation. Studies investigating intermittent PTH treatment in non-lethally irradiated mice showed similar trends as the clodronate-loaded liposome model (Koh et al., 2011) . Non-lethal irradiation caused a decrease in marrow cells, however CD68+ cells were expanded. Mice treated with PTH following irradiation showed an increased anabolic response (Koh et al., 2011) . Due to the large amount of apoptosis that occurs following irradiation, efferocytosis machinery is likely altered to compensate for the influx and may lead to an upregulation of CD68+ phagocytic cells. This is consistent with the findings seen in the clodronate-loaded liposome model, and suggests that intermittent PTH therapy is enhanced in an environment in which apoptotic cell clearance is increased. As was seen in the clodronate model, TGF-β gene expression in the marrow was increased in the irradiated mice, a factor which may potentiate PTH effects (Koh et al., 2011) . Additionally, mechanical ablation of bone marrow in rats resulted in an increase in bone formation which was further increased with intermittent PTH therapy (Zhang et al., 2012) .
Further support of the hypothesis that the effects of intermittent PTH therapy are dependent on the macrophage actions comes from metabololipidomic profiling . Intermittent PTH increased proresolving mediators, including resolvin D1 and D2, in the bone marrow. Resolvins participate in the resolution phase of inflammation and mediate efferocytosis (Dalli & Serhan, 2016) . Human and mouse derived macrophages displayed increased engulfment of apoptotic osteoblasts when primed with resolvin D1 and D2 . As macrophages do not have the PTH receptor, the mechanism by which PTH exerts its effects on macrophages is currently under investigation. PTH has been shown to have both pro-and anti-apoptotic effects on osteoblasts (Bellido et al., 2003; Chen et al., 2002) . In culture, early osteoblasts treated with PTH demonstrated decreased apoptosis, whereas mature osteoblasts treated with PTH displayed increased apoptosis. This led to the hypothesis that PTH promotes the apoptosis of less functional cells to promote reconstitution of the bone forming unit with younger, more functional osteoblasts. The increase in turnover of the osteoblast population may lead to the upregulation of alternatively activated M2-like macrophages and increased efferocytosis of apoptotic cells. The subsequent release of osteogenic factors leads to the recruitment of osteoblast precursors to facilitate the repopulation of the bone forming unit.
The exact mechanism by which PTH may regulate macrophages is unknown, as macrophages do not express the PTH receptor. Osteoblasts carry the PTH receptor and respond to PTH treatment. Osteoblasts treated with PTH show increased expression of macrophage responsive factors such as M-CSF (Weir et al., 1993) , IL-6 (Feyen, Elford, Di Padova, & Trechsel, 1989) , sIL-6R (Cho et al., 2013) , and chemokine (C-C motif) ligand 2 (Li, Qin, et al., 2007) . In the presence of PTH, osteoblasts may secrete factors which promote macrophage differentiation and recruitment, leading to increased availability of macrophages to exert their pro-anabolic effects on bone.
4. Potential for targeted therapy that modulate macrophages to increase bone regeneration Studies which have assessed the role of macrophages in the context of bone homeostasis have utilized models of macrophage ablation and characterized the aberrant effects. While these studies have shed light on the importance of this cell type on bone homeostasis, repair and anabolism, the ability to positively manipulate these cells to aid in bone regeneration is less appreciated. Clearly, targeting macrophages to assist in bone anabolism in cases of reduced bone mass or to aid in fracture repair shows promise in the field of bone biology. Colonystimulating factor-1 (CSF-1), mediates myeloid to monocyte, macrophage, dendritic cell and osteoclast differentiation (Hume & MacDonald, 2012; Metcalf, 1973; Stanley, Cifone, Heard, & Defendi, 1976) . CSF-1 has been investigated for its potential application in tissue repair including fracture healing (Hume & MacDonald, 2012; Sarahrudi et al., 2009 ). When CSF-1 was administered to rabbits during femoral osteotomy healing, mineralized bone was significantly increased compared to control groups (Sarahrudi et al., 2009) . Additional experiments employing the use of macrophage CSF-1 demonstrated that bone mass and formation are increased with CSF-1 treatment (Garceau et al., 2015; Lloyd et al., 2009) and in a mouse model of osteoporosis, M-CSF prevents ovariectomy-induced bone loss (Cenci, Weitzmann, Gentile, Aisa, & Pacifici, 2000) . Interestingly, recent studies have demonstrated that CSF-1 treatment increases osteal macrophages but not osteoclasts (Alexander et al., 2011; Raggatt et al., 2014) . This suggests that the ability to positively manipulate osteal macrophage numbers is a viable therapeutic target.
OSM released from macrophages has been shown to be anabolic in nature (Fernandes et al., 2013; Guihard et al., 2015 Guihard et al., , 2012 Nicolaidou et al., 2012; Walker et al., 2010) . The therapeutic potential of this molecule has been explored, and could potentially serve to enhance osteoblastic differentiation and mineralization. An early experiment tested the potential of an adenoviral vector encoding murine OSM injected into knee joints to alter inflammation and stimulate bone formation (de Hooge et al., 2002) . OSM was shown to increase joint inflammation, but also displayed increased bone apposition at periosteal sites which correlated with increased osteoblasts and decreased osteoclasts. Additionally, in lethally irradiated mice, OSM administration enhanced hematopoietic stem/progenitor cell recovery, suggesting OSM may serve to maintain the hematopoietic environment after injury. Like OSM, other factors that can be secreted by macrophages have been shown to be osteoinductive, including BMP-2 and could serve as potential therapies to enhance bone turnover.
The ability to directly target macrophages such that M1-like cells are decreased and M2-like cells are increased may facilitate the positive effects of macrophages on bone. Treating inflammation-induced bone loss has centered on targeting the production of Th1 by T cells to reduce inflammation and decrease osteoclast activity (Redlich & Smolen, 2012) . These therapies undoubtedly would have effects on macrophages as well. For example, Abatacept is a receptor construct that targets CD80/ CD86 and is used as an anti-inflammatory to treat rheumatoid arthritis (Westhovens et al., 2009) , and Tocilizumab is a humanized monoclonal antibody to IL-6R and is also used to treat rheumatoid arthritis as well as juvenile idiopathic arthritis (Kremer et al., 2011) . The exact effects of these therapeutics to alter macrophages in respect to bone turnover are not appreciated, but a better understanding of these processes can help identify optimal treatment regimens.
In an interesting study of rheumatoid arthritis, injection of apoptotic thymocytes into the peritoneum reduced the presentation of rheumatoid arthritis in a streptococcal cell wall-induced rheumatoid arthritis model (Perruche, Saas, & Chen, 2009 ). This was attributed to a decrease in TNF production by macrophages. This may also reflect an increase in resolution M2-like macrophages in response to the increased apoptotic cell insult. This further supports the idea that the process of efferocytosis results in favorable outcomes for bone in models of disease.
Other macrophage-targeted therapies under investigation
Altering macrophages to aid in the repair processes is not a new idea. In tissues other than bone, macrophages are potential targets for reducing symptoms of autoimmune diseases or enhancing tissue repair (Gordon, 2003) . While many of these targeted therapies are still being investigated in animal models, clues from these studies in non-bone tissues may aid in the development of macrophage-targeted therapies to alter bone formation and repair. It is thought than an imbalance in M1/M2 macrophages that favors proinflammatory M1 cells is the basis for many diseases and issues with healing. Targeting macrophages to increase M2-like macrophages may serve to decrease any negative effects seen by increased M1-like cells. There are many drugs that are antiinflammatory and could potentiate an M2 increase and a few will be reviewed here.
A well accepted paradigm in macrophage biology is IL-4 mediates macrophage phenotypic switch toward the alternatively activated M2-like state. In a mouse model of myocardial infarction, M2-like cells predominate after cardiac injury. When M2 macrophages were depleted, mice showed significantly worse prognoses when myocardial infarction was induced (Shiraishi et al., 2016) . Administration of IL-4 increased M2-like macrophages in mice and increased prognosis of myocardial infarcted mice. Early studies showed that IL-4 inhibits resorption (Watanabe et al., 1990 ), yet the therapeutic potential of IL-4 in fracture repair or osteoporosis therapy has not been thoroughly investigated and may serve as a positive regulator of repair and regeneration.
Another example of an approach to target macrophage polarization is CD200. CD200 interaction with its receptor increases alternatively activated macrophages (Hayakawa, Wang, & Lo, 2016) . Treatment of macrophages with human CD200-Fc up-regulated expression levels of M2-like markers and suppressed M1-like markers. These increases coincided with increased TGF-β expression in macrophages, and decreased proinflammatory macrophages. Interestingly, CD200 has been shown to play a role in bone turnover and CD200 signaling may be a future therapeutic target to promote M2-like macrophages to aid in tissue repair. Although promising, macrophage plasticity targets must be explored more thoroughly in animal models prior to pre-clinical settings to understand the complexity of the potential human response.
Conclusions and future directions
The heterogeneity of macrophages, their varying functional roles, and plasticity make them difficult but exciting targets for therapeutic intervention. In the context of bone, certain macrophage subsets have been shown to mediate turnover and healing. However, it must be noted that most strategies to target macrophages in bone will likely have off-target effects on osteoclasts. This review has outlined the known roles of macrophages in bone, the potential mechanisms behind their pro-osteogenic effects and the possibility to target macrophages to aid in bone related disease treatment and fracture healing. It is promising that macrophage stimulating molecules in combination with current approved osteoporosis therapies could improve patient outcomes. Clearly, more in depth characterization of macrophages in bone must be completed to identify the best possible strategies to target macrophages to aid in bone repair and regeneration.
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